Rep. Anna Eshoo

D

California – District 16

Leadership

Ranking Member Health

118th Congress

News & Announcements


Oct 8, 2024
Press Release

Bipartisan E&C Leaders Request FDA Briefing for More Details about Counterfeit Ozempic

Washington, D.C. — In a letter today to Food and Drug Administration (FDA) Commissioner Robert Califf, M.D., a bipartisan group of House Energy and Commerce Committee Leaders requested a briefing about the presence of counterfeit Ozempic and other semaglutide products in the United States’ medical supply chain.  The letter was signed by Chair Cathy McMorris Rodgers (R-WA) and Ranking Member Frank Pallone, Jr. (D-NJ); Subcommittee on Health Chair Brett Guthrie (R-KY) and Ranking Member Anna G. Eshoo (D-CA); and Subcommittee on Oversight and Investigations Chair Morgan Griffith (R-VA) and Ranking Member Kathy Castor (D-FL).   KEY LETTER QUOTE : “In addition to concerns about integrity gaps in the legitimate supply chain, we are also concerned about counterfeit Ozempic entering through illegal channels. For example, in June of this year, Eli Lilly issued an open letter expressing concern that counterfeit versions of its own drugs, Mounjaro and Zepbound, were being sold online, through social media and at medical spas. On May 1, 2024, a Department of Justice press release reported that work by FDA’s Office of Criminal Investigations resulted in the arrest of an individual for selling misbranded and adulterated weight loss drugs on TikTok. The Committee fully supports these continued investigations of unlawful sales.”   BACKGROUND :   The FDA alerted the public on December 21, 2023, to the presence of counterfeit Ozempic injection products in the legitimate drug supply; an investigati ve article l ater found that thousands of counterfeit Ozempic pens had arrived in a warehouse in Elmira, New York, as early as the fall of 2023. The fact that counterfeit medications made it into the legitimate medical supply chain raises concern about potential gaps in our supply chain security infrastructure.    This threat continues to grow.   CLICK HERE to read the full letter.



Sep 23, 2024
Press Release

Chair Rodgers Applauds House Passage of Nine Health Bills

Washington, D.C. — House Energy and Commerce Committee Chair Cathy McMorris Rodgers (R-WA) issued the following statement after the House passed nine health bills:  “These bipartisan bills will help improve the health and wellbeing of the American people, including individuals battling Alzheimer’s and children suffering from rare diseases, as well as those living with a disability. I’m grateful to my Energy and Commerce colleagues for moving the bills through regular order and will work to see them signed into law.”  BACKGROUND :  H.R. 8108 – To amend title XIX of the SSA to add a Medicaid State plan requirement with respect to determination of residency of certain individuals serving in Armed Forces:   Led by Reps. Jen Kiggans (R-VA) and Marcy Kaptur (D-OH)  Requires States to continue to provide Medicaid coverage for (or retain waiting list placement for) active-duty military families who are receiving home and community-based services (or are on the waitlist to receive such services) in the event that the family moves out of state for military relocation.  Passed the House unanimously.  Passed out of the House Energy and Commerce Committee unanimously on September 18, 2024.  S. 133 – NAPA Reauthorization Act :  Led by Senator Susan Collins (R-ME)  Reauthorizes and makes improvements to the National Alzheimer’s Project including expanding the membership of the project’s advisory council.   Passed the House unanimously.  House companion (H.R. 619), led by Reps. Paul Tonko (D-NY) and Chris Smith (R-NJ), passed out of the House Energy and Committee unanimously on March 20, 2024.  S. 134 – Alzheimer’s Accountability and Investment Act :  Led by Senator Susan Collins (R-ME)  Requires the NIH to continue to submit an annual budget estimate to Congress to achieve the initiatives and goals included in the National Plan to Address Alzheimer’s Disease.  Passed the House unanimously.  House companion (H.R. 620), led by Reps. Chris Smith (R-NJ) and Paul Tonko (R-NY), passed out of the House Energy and Commerce Committee unanimously on March 20, 2024.   H.R. 6829 – HEARTS Act :  Led by Rep. Frank Pallone, Jr. (D-NJ)  Promotes student access to AEDs and CPR in schools, including educational materials, training programs, and equipment.  Passed the House unanimously.  Passed out of the House Energy and Commerce Committee unanimously on March 20, 2024.  H.R. 3884 – Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act :  Led by Reps. Michael Burgess, M.D., (R-TX) and Danny Davis (D-IL)  Reauthorizes programs and activities under the CDC and the Health Resources and Services Administration (HRSA) aimed to support research, prevention, and treatment for sickle cell disease and other heritable blood disorders through fiscal year 2028.  Passed the House unanimously.  Passed out of the House Energy and Commerce Committee unanimously on July 19, 2023.  H.R. 2706 – Charlotte Woodward Organ Transplant Discrimination Prevention Act :  Led by Reps. Kat Cammack (R-FL) and Debbie Dingell (D-MI)  Prohibits health care providers and other entities from denying or restricting an individual's access to organ transplants solely based on an individual's disability, except in limited circumstances.  Passed the House unanimously.  Passed out of the House Energy and Commerce Committee unanimously on March 20, 2024.  H.R. 5526 – Seniors’ Access to Critical Medications Act :  Led by Reps. Diana Harshbarger (R-TN) and Debbie Wasserman Schultz (D-FL)  Amends the physician self-referral law to permit Medicare patients to receive prescription drugs via caregivers picking up drugs on the patient’s behalf or via mail or couriers delivering the drug to the patient in instances when a provider prescribes a drug to be dispensed by a pharmacy that falls under the self-referral law’s definition of an in-office ancillary service.  Passed the House unanimously.  Passed out of the House Energy and Commerce Committee unanimously on June 12, 2024.  H.R. 3433 – Give Kids a Chance Act :  Led by Reps. Michael McCaul (R-TX) and Anna Eshoo (D-CA)  R eauthorizes the Food and Drug Administration (FDA) rare pediatric disease priority review voucher (PRV) program through fiscal year 2029.  Requires the FDA to establish an office in an Abraham Accord country.  Allows the Secretary of Health and Human Services to collect registration fees and distribute these fees to support the operation of Organ Procurement and Transplantation Network.  Passed the House unanimously.  Passed out of the House Energy and Commerce Committee unanimously on September 18, 2024.  H.R. 7189 – Congenital Heart Futures Reauthorization Act :  Led by Reps. Gus Bilirakis (R-FL) and Darren Soto (FL)  Reauthorizes and makes improvements to the national congenital heart disease research, surveillance, and awareness program at the CDC through fiscal year 2029.  Passed the House unanimously.  Passed out of the House Energy and Commerce Committee unanimously on March 20, 2024. 



Apr 15, 2024
Press Release

Bipartisan E&C Committee Leaders Seek Answers from UnitedHealth Group on Change Healthcare Cyberattack

Washington D.C. — House Energy and Commerce Committee Chair Cathy McMorris Rodgers (R-WA) and Ranking Member Frank Pallone, Jr., (D-NJ), Subcommittee on Health Chair Brett Guthrie (R-KY) and Ranking Member Anna G. Eshoo (D-CA), and Subcommittee on Oversight and Investigations Chair Morgan Griffith (R-VA) and Ranking Member Kathy Castor (D-FL) wrote to UnitedHealth Group, Inc., CEO Andrew Witty today seeking information about the cyberattack on Change Healthcare. Change Healthcare, which was acquired by UnitedHealth Group’s Optum subsidiary in 2022, is one of the nation’s largest providers of health care payment management systems. On February 21, UnitedHealth Group reported it had experienced a cyberattack on its platforms, and it had taken all Change Healthcare systems offline to contain the incident. As a result of the outage, critical services affecting patient care—including billing services, claims transmittals, and eligibility verifications—became inoperable. Though UnitedHealth first notified users that it expected the disruption to “last at least through the day,” several of the company’s products have now been inoperable for more than a month. “Change Healthcare is a central player in the country’s health care system, which has been upended by the recent breach,” t he bipartisan Committee leaders wrote to Mr. Witty. “We are interested in your efforts to secure Change Healthcare’s systems since it was acquired by your company and the efforts you are taking to restore system functionality and support patients and providers affected by the attack.” Change Healthcare’s platforms touch an estimated one in three U.S. patient records. Its systems process roughly 15 billion transactions annually, and are linked to approximately 900,000 physicians, 118,000 dentists, 33,000 pharmacies, and 5,500 hospitals nationwide. The breadth of Change Healthcare’s infrastructure all but ensures that the scope of the current disruption, and any disruption in Change Healthcare services, will be extensive. “The health care system is rapidly consolidating at virtually every level, creating fewer redundancies and more vulnerability to the entire system if an entity with significant market share at any level of the system is compromised,” the Committee leaders wrote. “In order to understand better the steps UnitedHealth has taken to address this situation, we request information about the impact of the cyberattack, the actions the company is taking to secure its systems, and the outreach to the health care community in the aftermath.” As a result of the system outage, providers reportedly struggled to make payroll while some patients have been forced to pay out of pocket for crucial medications including cancer therapy drugs and insulin because pharmacies are unable to verify coverage. The Committee leaders requested answers to a series of detailed questions by April 29, 2024. CLICK HERE to read the full letter.